ZGNX

Zogenix, Inc. [ZGNX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ZGNX Stock Summary

In the News

08:00 30 Nov 2023 ZGNX

Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022

EMERYVILLE, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that new data from the company's research and development program for FINTEPLA® (fenfluramine) in Lennox Gastaut syndrome (LGS) will be presented at the hybrid American Academy of Neurology (AAN) Annual Meeting 2022, in-person in Seattle (April 2-7) and held virtually (April 24-26).

10:45 30 Nov 2023 ZGNX

Zogenix (ZGNX) Reports Q4 Loss, Tops Revenue Estimates

Zogenix (ZGNX) delivered earnings and revenue surprises of -8.89% and 1.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

08:33 30 Nov 2023 ZGNX

Why Zogenix Flew Higher Before Leveling Off This Week

The company attracts a determined suitor from abroad.

10:07 30 Nov 2023 ZGNX

Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist

Which biotech stocks are you watching today?

01:04 30 Nov 2023 ZGNX

Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCB

Belgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022.

09:59 30 Nov 2023 ZGNX

Zogenix (ZGNX) Stock Jumps 65.7%: Will It Continue to Soar?

Zogenix (ZGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

11:44 30 Nov 2023 ZGNX

ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today

Zogenix (ZGNX) stock is skyrocketing on Wednesday following news that UCB (UCBJY) intends to acquire the company in a $1.9 billion deal. The post ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today appeared first on InvestorPlace.

10:18 30 Nov 2023 ZGNX

Why Zogenix Stock Is on Fire Today

A buyout deal is lighting a fire underneath the biotech's shares today.

09:38 30 Nov 2023 ZGNX

Why Zogenix Shares Are Soaring Today

Zogenix Inc (NASDAQ: ZGNX) is trading significantly higher Wednesday morning after the company announced it received a proposal to be acquired by UCB for approximately $1.9 billion. Under terms of the agreement, UCB will offer to purchase all outstanding shares of Zogenix for $26 per share in cash at closing.

07:34 30 Nov 2023 ZGNX

Zogenix Stock (ZGNX): Why The Price Went Up Substantially Today

The stock price of Zogenix, Inc. (NASDAQ: ZGNX) increased by over 60% pre-market today. This is why it happened.

ZGNX Financial details

Company Rating
Neutral
Market Cap
0
Income
-227.41M
Revenue
81.69M
Book val./share
3.2
Cash/share
5.39
Dividend
-
Dividend %
-
Employees
327
Optionable
No
Shortable
Yes
Earnings
28 Feb 2022
P/E
-6.3
Forward P/E
-
PEG
-14.45
P/S
-
P/B
8
P/C
4.95
P/FCF
-
Quick Ratio
3.19
Current Ratio
3.63
Debt / Equity
1.62
LT Debt / Equity
0.93
-
-
EPS (TTM)
-4.07
EPS next Y
-
EPS next Q
-
EPS this Y
8.72%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-1.83%
Revenue last 5Y
52.76%
Revenue Q/Q
17.68%
EPS Q/Q
-5.77%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
105.43%
Inst Trans
1.03%
ROA
-49%
ROE
-83%
ROC
-0.6%
Gross Margin
94%
Oper. Margin
-274%
Profit Margin
-278%
Payout
-
Shs Outstand
56.23M
Shs Float
48.51M
-
-
-
-
Target Price
26
52W Range
26.51-26.9
52W High
+2.62%
52W Low
+2.62%
RSI
-
Rel Volume
3.63
Avg Volume
3.1M
Volume
11.25M
Perf Week
0%
Perf Month
0%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
0.899114
-
-
Volatility
0%, 0%
Prev Close
0%
Price
26.68
Change
0.64%

ZGNX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.3600.080.251.52
Net income per share
-4.65-3.27-9.74-3.9-4.24
Operating cash flow per share
-2.78-2.95-2.59-3.12-3.45
Free cash flow per share
-2.78-2.97-2.81-3.33-3.45
Cash per share
10.7513.575.839.415.62
Book value per share
11.0413.85.696.893.33
Tangible book value per share
7.0610.933.174.931.53
Share holders equity per share
11.0413.85.696.893.33
Interest debt per share
0.100.032.883.42
Market cap
1.09B1.38B2.25B1.07B872.43M
Enterprise value
799.9M1.31B2.2B1.06B939.73M
P/E ratio
-8.62-11.15-5.35-5.13-3.84
Price to sales ratio
111.330615.4778.6610.68
POCF ratio
-14.41-12.37-20.13-6.41-4.71
PFCF ratio
-14.4-12.26-18.55-6-4.71
P/B Ratio
3.632.649.162.94.87
PTB ratio
3.632.649.162.94.87
EV to sales
81.450601.7777.511.5
Enterprise value over EBITDA
-6.46-10.61-5.25-4.86-4.64
EV to operating cash flow
-10.54-11.76-19.68-6.31-5.07
EV to free cash flow
-10.53-11.65-18.14-5.91-5.07
Earnings yield
-0.12-0.09-0.19-0.2-0.26
Free cash flow yield
-0.07-0.08-0.05-0.17-0.21
Debt to equity
0.390.240.690.761.62
Debt to assets
0.280.190.410.430.62
Net debt to EBITDA
2.370.550.120.07-0.33
Current ratio
14.529.133.016.313.63
Interest coverage
-45.36-23.53K-214.91K-65.9-14.67
Income quality
0.60.90.270.80.81
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
2.1509.227.30
Research and developement to revenue
6.87031.710.121.75
Intangibles to total assets
0.260.170.260.160.21
Capex to operating cash flow
00.010.090.070
Capex to revenue
-0.010-2.6-0.830
Capex to depreciation
-0.18-6.57-7.49-2.08-0.01
Stock based compensation to revenue
0.6305.822.140.43
Graham number
33.9831.8635.3124.5817.82
ROIC
0.69-0.28-1.52-0.75-0.92
Return on tangible assets
-0.41-0.23-1.37-0.38-0.61
Graham Net
6.510.261.94.230.42
Working capital
283.72M474.36M191.85M439.46M256.87M
Tangible asset value
192.79M414.07M136.33M264.88M82.06M
Net current asset value
188.61M407.2M118.05M240.71M65.05M
Invested capital
000.010.410.94
Average receivables
6.29M001.91M6.98M
Average payables
3.95M5.67M7.98M9.96M16.97M
Average inventory
3.52M00513K3.26M
Days sales outstanding
000102.3145.3
Days payables outstanding
114.17008.04K1.66K
Days of inventory on hand
000690.94414.68
Receivables turnover
0003.578.06
Payables turnover
3.2000.050.22
Inventory turnover
0000.530.88
ROE
-0.42-0.24-1.71-0.57-1.27
Capex per share
0-0.03-0.22-0.210

Quarterly Fundamentals Overview

Last date of statement is 2021-12-31 for Q4

Metric History 2020-12-312021-03-312021-06-302021-09-30 2021-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.150.250.340.40.48
Net income per share
-1.26-1-1.05-1.04-0.98
Operating cash flow per share
-0.69-0.97-0.77-0.85-0.73
Free cash flow per share
-0.8-0.97-0.77-0.85-0.73
Cash per share
9.077.817.046.145.39
Book value per share
6.645.764.894.013.2
Tangible book value per share
4.763.923.082.241.47
Share holders equity per share
6.645.764.894.013.2
Interest debt per share
2.782.993.023.053.08
Market cap
1.11B1.09B964.85M849.2M910.05M
Enterprise value
1.1B1.16B990.68M909.64M977.35M
P/E ratio
-3.97-4.89-4.1-3.66-4.15
Price to sales ratio
130.9479.5351.3537.5634.2
POCF ratio
-29.18-20.21-22.47-17.92-22.13
PFCF ratio
-25.09-20.17-22.47-17.92-22.13
P/B Ratio
3.013.393.543.795.08
PTB ratio
3.013.393.543.795.08
EV to sales
129.0785.1352.7340.2336.73
Enterprise value over EBITDA
-17.14-23.52-18.78-17.56-20.15
EV to operating cash flow
-28.76-21.63-23.08-19.2-23.76
EV to free cash flow
-24.73-21.59-23.08-19.2-23.76
Earnings yield
-0.06-0.05-0.06-0.07-0.06
Free cash flow yield
-0.04-0.05-0.04-0.06-0.05
Debt to equity
0.760.810.981.221.62
Debt to assets
0.430.450.490.550.62
Net debt to EBITDA
0.25-1.55-0.49-1.17-1.39
Current ratio
6.317.776.014.793.63
Interest coverage
-18.03-13.86-14.63-14-16.14
Income quality
0.540.970.730.820.75
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
3.440000
Research and developement to revenue
4.232.261.951.471.57
Intangibles to total assets
0.160.180.190.20.21
Capex to operating cash flow
0.160000
Capex to revenue
-0.73-0.01000
Capex to depreciation
-2.64-0.04000
Stock based compensation to revenue
0.860.590.510.360.36
Graham number
13.7211.3710.779.688.39
ROIC
-0.22-0.13-0.22-0.2-0.26
Return on tangible assets
-0.13-0.12-0.13-0.15-0.15
Graham Net
4.083.252.391.420.4
Working capital
439.46M396.2M347.05M297.04M256.87M
Tangible asset value
264.88M218.46M172.01M125.42M82.06M
Net current asset value
240.71M195.05M149.18M102.77M65.05M
Invested capital
0.410.510.60.740.94
Average receivables
2.57M4.97M6.91M8.59M9.81M
Average payables
9.58M11.95M11.4M11.47M17.06M
Average inventory
1.02M1.68M2.62M3.21M4.5M
Days sales outstanding
40.4840.2436.8937.7634.29
Days payables outstanding
2.67K1.59K797.7842.481.21K
Days of inventory on hand
229.7309.41215.28243.57301.02
Receivables turnover
2.222.242.442.382.62
Payables turnover
0.030.060.110.110.07
Inventory turnover
0.390.290.420.370.3
ROE
-0.19-0.17-0.22-0.26-0.31
Capex per share
-0.110000

ZGNX Frequently Asked Questions

What is Zogenix, Inc. stock symbol ?

Zogenix, Inc. is a US stock , located in Emeryville of California and trading under the symbol ZGNX

Is Zogenix, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $26. The lowest prediction is $26 and the highest is $26

What is ZGNX stock prediction ?

What is Zogenix, Inc. stock quote today ?

Zogenix, Inc. stock price is $26.68 today.

Is Zogenix, Inc. stock public?

Yes, Zogenix, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Similar Market Cap